CREE TUES AH (R@55) Cree reiterated as an Underweight at BofA/Merrill BofA/Merrill said it remains confident in its Underperform thesis for Cree and does not recommend putting new money to work. The firm expects gross margins to be pressured longer-term due to increasing competition from new entrants. Price target is $19.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.